| Literature DB >> 20356399 |
Nguyen Quynh Hoa1, Nguyen V Trung, Mattias Larsson, Bo Eriksson, Ho D Phuc, Nguyen Tk Chuc, Cecilia Stalsby Lundborg.
Abstract
BACKGROUND: Streptococcus pneumoniae is the most significant bacterial cause of community-acquired pneumonia among children under five years worldwide. Updated resistance information of S. pneumoniae among children is essential to adjust the recommendations for empirical treatment of community-acquired pneumonia, which will have immense implications for local and global health. This study investigated the prevalence of antibiotic resistance in isolated strains of S. pneumoniae and relationship with antibiotic use and demographic factors of children under five in rural Vietnam in 2007.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20356399 PMCID: PMC2853544 DOI: 10.1186/1471-2334-10-85
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Characteristics of 818 community children aged 6-60 months and estimated prevalence of S. pneumoniae nasopharyngeal carriage.
| Characteristics | Absolute number with percentage in bracket | ||
|---|---|---|---|
| Participating children | |||
| Female | 373 (46) | 187 (50) | |
| Male | 445 (54) | 234 (53) | |
| 6-23 months | 367 (45) | 203 (55)* | |
| 24-60 months | 451 (55) | 218 (48)* | |
| Lowland | 268 (32) | 145 (54) | |
| Highland | 275 (34) | 146 (53) | |
| Mountains | 275 (34) | 130 (47) | |
| Under average | 358 (44) | 196 (55) | |
| Average or upper | 460 (56) | 225 (49) | |
| No presence | 560 (68) | 265 (47)* | |
| Presence | 258 (32) | 156 (61)* | |
| No presence | 650 (80) | 340 (52) | |
| Presence | 168 (20) | 81 (48) | |
| No | 341 (42) | 183 (54) | |
| Yes | 477 (58) | 238 (50) | |
| Total | 818 (100) | 421 (52) | |
* Significant different between groups using χ2 test (p < 0.05).
§ Other observations: Non-ARI symptoms such as digestive disorder, skin rash, toothache, phymosis.
Susceptibility of 421 S. pneumoniae isolates to antibiotic agents
| Antibiotic agents | ATC code | Absolute number and percentage in bracket | ||
|---|---|---|---|---|
| Resistant (R) | Intermediate (I) | Susceptible (S) | ||
| Tetracycline | J01AA07 | 314 (75) | 44 (10) | 63 (15) |
| Benzylpenicillin | J01CE01 | 17 (4) | 136 (32) | 268 (64) |
| Phenoxymethylpenicillin* | J01CE02 | 315 (75) | - | 106 (25) |
| Ampicillin** | J01CA01 | 17 (4) | 136 (32) | 268 (64) |
| Amoxicillin** | J01CA04 | 17 (4) | 136 (32) | 268 (64) |
| Cefotaxime | J01DD01 | 9 (2) | 14 (3) | 398 (95) |
| Co-trimoxazole | J01EE01 | 329 (78) | 47 (11) | 45 (11) |
| Erythromycin | J01FA01 | 294 (70) | 52 (12) | 75 (18) |
| Ciprofloxacin | J01MA02 | 119 (28) | 296 (70) | 6 (2) |
* Susceptibility to phenoxymethylpenicillin is derived from benzylpenicillin MICs according to EUCAST documents.
** Susceptibility to ampicillin and amoxicillin are derived from benzylpenicillin MICs according to CLSI documents.
Figure 1Distribution of estimated minimum inhibitory concentration (MIC) by Etest. Figure 1 shows the distribution of estimated minimum inhibitory concentration (MIC) for penicillin (a) and cefotaxime (b) against 421 S. pneumoniae isolates.
Figure 2Distribution of estimated inhibitory zone diameter by disk diffusion. Figure 2 shows the distribution of estimated inhibitory zone diameter by disk diffusion for tetracycline (a), co-trimoxazole (b), erythoromycin (c) and ciprofloxacin (d) against 421 S. pneumoniae isolates.
Antibiotic resistance in relation to background characteristics of the 421 S. pneumoniae carriers.
| Characteristics | Percentage of resistant strains among total carriers within each category | |||||||
|---|---|---|---|---|---|---|---|---|
| TET† | PEN G† | PEN V† | CTX† | SXT† | ERY† | CIP† | MDR† | |
| - FemaleR (187) | 68* | 5 | 72 | 3 | 78 | 67 | 25 | 56 |
| - Male (234) | 80* (**) | 3 | 77 | 1 | 79 | 72 | 31 | 63 |
| - 6-23 monthsR (217) | 75 | 4 | 76 | 3 | 78 | 73 | 27 | 61 |
| - 24-60 months (204) | 74 | 2 | 74 | 2 | 78 | 67 | 29 | 59 |
| - LowlandR (145) | 77 | 2 | 78 | 0* | 74* | 68* | 32 | 55* |
| - Highland (146) | 72 | 6 | 77 | 5* | 74* | 64* | 24 | 56* |
| - Mountains (130) | 75 | 4 | 69 | 2* | 88* (**) | 78* | 29 | 70* (**) |
| - Under averageR (203) | 79 | 5 | 76 | 3 | 80 | 72 | 31 | 61 |
| - Average or upper (218) | 71 | 3 | 74 | 1 | 76 | 68 | 26 | 59 |
| - NoR (183) | 73 | 3 | 68* | 0.5* | 73* | 67 | 26 | 56 |
| - Yes (238) | 76 | 5 | 80*(**) | 3* | 82*(**) | 72 | 30 | 63 |
| Total (421) | 75 | 4 | 75 | 2 | 78 | 70 | 28 | 60 |
* p < 0.05: significant different between groups using χ2 test.
** Significant difference between group vs. reference using multiple logistic regression analysis.
R Reference groups in multiple logistic regression analysis
† TET: tetracycline, PEN G: benzylpenicillin, AMX: amoxicillin, AMP: ampicillin, PEN V: phenoxymethylpenicillin, CTX: cefotaxime, SXT: co-trimoxazole, ERY: erythromycin, CIP: ciprofloxacin, MDR: multidrug-resistant.
Pattern of co-resistance to tested antibiotics among 421 S. pneumoniae isolates
| Individual antibiotic and combination | Absolute number of co-resistance with percentage of total 421 isolates in bracket | |||||||
|---|---|---|---|---|---|---|---|---|
| CIP† | PEN G† | CTX† | CIP-PEN G | CIP- | PEN G-CTX | CIP- CTX - PEN G | ||
| 119 (28) | 17 (4) | 9 (2) | 1 (0.2)* | 2 (0.5) | 5 (1)* | 0 (0) | ||
| SXT† | 329 (78) | 86 (20) | 17 (4)* | 9 (2) | 1 (0.2) | 2 (0.5) | 5 (1) | 0 (0) |
| TET† | 314 (75) | 99 (24)* | 13 (3) | 7 (2) | 1 (0.2) | 2 (0.5) | 3 (1) | 0 (0) |
| ERY† | 294 (70) | 66 (16)* | 15 (4) | 6 (1) | 1 (0.2) | 0 (0) | 4 (1) | 0 (0) |
| SXT - TET | 254 (60)* | 73 (17) | 13 (3) | 7 (2) | 1 (0.2) | 2 (0.5) | 3 (1) | 0 (0) |
| SXT - ERY | 248 (59)* | 51 (12) | 15 (4) | 6 (1) | 1 (0.2) | 0 (0) | 4 (1) | 0 (0) |
| TET - ERY | 241 (57)* | 60 (14) | 13 (3) | 5 (1) | 1 (0.2) | 0 (0) | 3 (1) | 0 (0) |
| SXT-TET-ERY | 200 (48) | 45 (11) | 13 (3) | 5 (1) | 1 (0.2) | 0 (0) | 3 (1) | 0 (0) |
*Significant different between resistant groups vs. non-resistant groups using χ2 test (p < 0.05).
† TET: tetracycline, PEN G: benzylpenicillin, CTX: cefotaxime, SXT: co-trimoxazole, ERY: erythromycin, CIP: ciprofloxacin.
Figure 3Change of estimated susceptibility prevalence of . Figure 3 compares the estimated susceptibility prevalence to five antibiotics between 421 S. pneumoniae isolates in 2007 and 106 isolates in 1999 in Bavi district.